CIL004

CIL004 (also known as CIL-004) is a preclinical-stage drug candidate being developed by Cilcare, a biotechnology company specializing in the field of otology. The program is specifically focused on the treatment of ear inflammation, a condition that can contribute to various auditory disorders and hearing loss. As of early 2024, CIL004 remains in the preclinical phase of development, and while it is a key component of Cilcare's internal pipeline, the company has not yet publicly disclosed its specific molecular target, mechanism of action, or modality. Cilcare leverages its expertise in auditory research and specialized pharmacological models to advance candidates like CIL004 toward clinical evaluation.